ANIK — Anika Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $364.59m
- $301.77m
- $166.66m
- 86
- 25
- 81
- 68
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 185 | 98.3 | 94.4 | 86.3 | 72.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 23.1 | 24.1 | 29.8 | 34.6 | 36 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 234 | 177 | 169 | 170 | 163 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 73.6 | 73.2 | 68.6 | 79 | 75 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 331 | 366 | 348 | 349 | 271 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 16.3 | 36.9 | 29.8 | 27.9 | 31.1 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 42.3 | 93.2 | 60.5 | 63.6 | 58.4 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 288 | 272 | 287 | 286 | 212 |
Total Liabilities & Shareholders' Equity | 331 | 366 | 348 | 349 | 271 |
Total Common Shares Outstanding |